

AFC THERAPEUTIC USE EXEMPTION (TUE) POLICY

The AFC Therapeutic Use Exemption Policy (“Policy”) outlines the procedures governing the application, approval, mutual recognition and administrative management of Therapeutic Use Exemptions (TUEs) within AFC’s jurisdiction and in accordance with International Standard for Therapeutic Use Exemption issued by WADA (World Anti-Doping Agency).

The AFC TUE Policy is based on the following documents currently in force:

- AFC Anti-Doping Regulations (AFC ADR);
- World-Anti Doping Code (WADC) issued by WADA;
- International Standard for Therapeutic Use Exemption (ISTUE) published by WADA.

Contents

1. Scope	1
2. Granting body.....	2
3. Criteria for granting TUEs.....	3
4. TUE Application process.....	3
5. AFC TUE Policy involving glucocorticoids	5
6. Mutual recognition of TUE approvals	7
7. TUE Approvals	8
8. Data protection	8
ANNEXE 1.....	12
ANNEXE 2	14

1. Scope

The purpose of the Policy is to ensure that the process of granting TUEs is standardised/uniform for all players participating in AFC competitions and is harmonised across all Member Associations.

This Policy defines the criteria for granting a TUE, the confidentiality and protection of TUE- related data, the TUE application and approval process, and the mutual recognition of TUE approvals by FIFA and other confederations.

This Policy is applicable to all players participating in AFC competitions for which AFC has indicated that a TUE from AFC is required as well as those in the AFC registered testing pool, AFC individual athlete testing pool (IATP), the elite testing pool (ETP) and the AFC pre- competition testing pool (PCTP)) in accordance with Article 19.5 of the AFC ADR. To facilitate participation in international competitions, this Policy has been adopted and is consistent with the FIFA TUE policy.

2. Granting body

The AFC Medical Committee has overall responsibility for approving applications for TUEs. It delegates the evaluation and the approval of TUEs to the AFC TUE Advisory Group. The AFC TUE Advisory Group includes three (3) doctors with experience in the care and treatment of players and a sound knowledge of clinical, sports and exercise medicine. The AFC TUE Advisory Group is free of any conflict of interest. The AFC TUE Advisory Group may seek whatever medical or scientific expertise it deems appropriate to review the circumstances of any application for a TUE. The AFC TUE Advisory Group aims to render its decision within twenty-one (21) days of receipt of all requested information.

In compliance with Article 19.5 of the AFC ADR and Article 4.4.3 of the WADC, the AFC TUE Advisory Group recognises or grants TUE approvals for:

- players registered to participate in all AFC competitions and/or competitions under the jurisdiction of AFC (for a list of AFC's competitions, see Annex 1); or
- players designated by AFC and/or another confederation and/or FIFA as being within AFC's or another confederation's or FIFA's registered testing pool.

Accordingly, TUE applications for the recognition or grant of a TUE for international-level players must be sent to the AFC Anti-Doping Unit for the attention of the AFC TUE Advisory Group unless there is an agreement of mutual recognition with other granting bodies (see Table 1 and section IV) in accordance with Article 7 of the ISTUE.

Level of Play	TUE application to be sent to	Application to be submitted by
National players participating in domestic competitions only	National Anti-Doping organisation (NADO) or other authorised national body (e.g. National Olympic Committee)	Player
International players called up to compete in international team competitions and friendly matches at AFC level; or who are part of an AFC registered testing pool; or who are part of the FIFA elite testing pool.	AFC	Player
International players participating in AFC club competitions; or who are part of an AFC elite testing pool	AFC	Player

International players participating in FIFA competitions (incl. FIFA World Cup TM qualifying matches) or who are part of FIFA pre-competition testing pool.	FIFA TUEs granted by the AFC are automatically recognised by FIFA	Player
Players in FIFA International registered testing pool.	FIFA TUEs granted by the AFC are automatically recognised by FIFA	Player
Players participating in other major event organisations tournaments (e.g. Olympic Football Tournaments)	TUEC of the major event organisation (TUEs granted by confederations are automatically recognised)	Player

Table 1: Granting bodies for TUEs in football

3. Criteria for granting TUEs

TUE applications submitted to the AFC shall be evaluated according to the criteria for granting a TUE defined in Annex B of the AFC ADR and Article 4 of the ISTUE.

4. TUE Application process

It is the player's responsibility to ensure that all information for the TUE application is accurate and up to date.

A TUE shall only be considered on receipt of a completed application form that must include all relevant documents (see Annex 2 - TUE application form) and follow the principles laid out in Annex B of the AFC ADR.

- Players included either in the AFC registered testing pool and players participating in any AFC competition must obtain a TUE from the AFC. Players already in possession of a valid TUE must adhere to the following procedures:
 - If the TUE was granted by FIFA or another confederation, then it will automatically be recognised by the AFC.
 - If the TUE was granted by a NADO or other relevant national body with the competence to grant a TUE, the player shall provide AFC with the granted TUE and the supporting documents at the latest twenty-one (21) days before the beginning of the respective AFC competition (see also Annex B of the AFC ADR and Section 7 of the ISTUE)
- The player should submit an application for a TUE no less than thirty (30) days before he or she needs the approval (e.g. for an AFC competition), unless it is an emergency or exceptional situation (see possibility of an application for a retroactive TUE of the Annex B of the AFC ADR).

- The TUE application form that appears as an annex to the ISTUE has been modified by the AFC to include additional requests for information, as set out in Annex 2.
- The TUE application form is provided by the AFC in English and will need to be completed in English in fully legible writing. The medical file, including all documents and reports, must also be provided in English. As a first step, please send a formal email only to s.medicine@the-afc.com, without attaching the TUE application form or relevant medical documents. The AFC will send you a personalised link to an encrypted folder. You will then be asked to upload the TUE application form and the relevant medical documents into that encrypted folder. Please do not send personal information via email and/or other communication modes except via the personalised link sent by the AFC.
- The application must identify the player's affiliation, and the specific competition, if applicable, for which the application is being made.
- The application must list any or all previous and/or current TUE requests, the body to whom that request was made, and the decision of any other body on review or appeal.
- The application must include a comprehensive medical history and the results of all examinations, laboratory investigations and imaging studies relevant to the application. The medical information provided to support the diagnosis and treatment, as well as the duration of validity, should follow WADA's "*Medical Information to Support the Decisions of TUECs*".
- On its website, WADA publishes a "Medical Information to Support the Decisions of TUECs" to guide and assist AFC TUE Advisory Group or other TUECs in the decision- making process for TUE applications. These documents contain helpful information for practitioners when dealing with players who need specific treatment, such as:

- <i>ADHD (Attention Deficit Hyperactivity Disorder) in Children and Adult</i> - <i>Adrenal Insufficiency</i> - <i>Anaphylaxis</i> - <i>Asthma</i> - <i>Cardiovascular Condition: the Therapeutic Use of Beta-blockers in Athletes</i> - <i>Diabetes Mellitus</i> - <i>Growth Hormone Deficiency in Adults</i> - <i>Growth Hormone Deficiency in Children and Adolescents</i>	- <i>Infertility/Polycystic Ovarian Syndrome</i> - <i>Inflammatory Bowel Disease</i> - <i>Intravenous Infusion</i> - <i>Intrinsic Sleep Disorders</i> - <i>Male Hypogonadism</i> - <i>Musculoskeletal Conditions</i> - <i>Neuropathic Pain</i> - <i>Renal Transplantation</i> - <i>Sinusitis/Rhinosinusitis</i> - <i>Transgender Athletes</i>
--	--

These documents and the TUE Checklist provided by WADA are available at: <https://www.wada-ama.org/en/resources/therapeutic-use-exemption>

- Any additional relevant investigations, examinations or imaging studies requested by the AFC TUE Advisory Group before approval shall be undertaken at the expense of the applicant or his or her national governing body/club.
- The application must include a statement by a qualified doctor attesting to the necessity of the otherwise prohibited substance or prohibited method in the treatment of the player and describing why an alternative, permitted medication cannot, or could not, be used in the treatment of this condition.
- The substance in question must be given its generic name. Brand names will not be accepted and will lead to the application being returned. The dose, frequency, route and duration of administration of the otherwise prohibited substance or prohibited method in question must be specified. If any of the above changes, a new application will need to be submitted.
- In normal circumstances, the decisions of the AFC TUE Advisory Group should be completed within twenty-one (21) days of receipt of all relevant documentation and shall be conveyed in writing by the AFC Anti-Doping Unit using the contact details indicated by the player on the TUE application. In the case of TUE applications not made within the required time limit but made within a reasonable time limit prior to a competition, the AFC TUE Advisory Group shall make every effort to complete the TUE process before the start of the competition. Where a TUE has been granted to a player in the AFC registered testing pool or a player participating in an AFC competition, the player and WADA shall promptly be provided with approval that includes information pertaining to the duration of the TUE and any conditions associated with it.
- A player may request a review by the WADA TUEC in accordance with Article 4.4.6 of the WADC. The player must provide the WADA TUEC with all of the information on the TUE that was initially submitted to the AFC TUE Advisory Group, accompanied by an application fee. Until the review process has been completed, the original decision of the AFC TUE Advisory Group shall remain in effect.
- If a decision regarding the granting of a TUE is reversed by WADA upon review, the reversal shall not apply retroactively and shall not disqualify the player's results during the period that the TUE had been granted.
- WADA, at the request of a player or on its own initiative, may review the granting or denial of any TUE by the AFC. Decisions by WADA reversing the granting or denial of a TUE may be appealed exclusively to the Court of

Arbitration for Sport (CAS) by the player, the player's NADO or the AFC.

5. **AFC TUE Policy involving glucocorticoids**

As of the 2022 Prohibited List, glucocorticoids (GCs) are prohibited in-competition when administered by all injectable, oral or rectal routes. Examples of injectable routes of administration include intravenous, intramuscular, periarticular, intraarticular, peritendinous, intratendinous, epidural, intrathecal, intrabursal, intralesional (e.g. intrakeloid), intradermal and subcutaneous. It should be noted that all oral routes of administration of GCs remain prohibited, including oromucosal, buccal, gingival and sublingual routes. All other routes of administration, including inhalation, intranasal spray, ophthalmological drops, perianal, dermal, dental intracanal application and topical applications are permitted at all times and do not require a TUE.

WADA has also increased the reporting limits for WADA-accredited laboratories for GCs. This approach is being introduced to better indicate when a GC has been administered by a prohibited rather than permitted route.

A player risks being sanctioned when a GC, its metabolites or its markers are found to exceed the laboratory reporting levels in a urine sample collected in-competition. As per the AFC ADR, an in-competition sample may be collected from 23:59 hours on the day before the match until the end of the sample collection procedure relating to said match.

Out-of-competition use of GCs, by any route, is not prohibited. However, an in-competition urine sample may contain evidence of the use of GCs even though this took place out-of- competition, and an adverse analytical finding (AAF) may be reported. If the player and attending physician provide appropriate clinical justification for the use of GCs, a retroactive TUE may be granted according to Article 4.1e of ISTUE. However, if no TUE is granted, the AAF may lead to a sanction.

This new approach will affect the period in which a player's sample can return an AAF following the administration depending on the type, route and dose of the GC administered. This has prompted WADA to devise so-called "washout periods" in the lead-up to a match, which takes these factors into account and advises players when a TUE might be needed. Further information about WADA's decision to make changes to the way GCs are regulated in sport can be found in a review article published in the British Journal of Sports Medicine¹.

Washout periods following the administration of GCs


After the administration of GCs, urinary reporting levels, which would result in an AAF, can be reached for different periods of time (ranging from days to weeks), depending on the GC administered, the route and the dose. To reduce the risk of an AAF, players should adhere to the minimum washout periods.

A washout period in this context refers to the time starting from the last administered dose and ending when the in-competition period starts. This is to give enough time for the GC to be metabolised below the reporting level. These washout periods are based on the use of these medications according to the manufacturer's maximum licensed doses:

Route	Glucocorticoid	Washout Period
Oral	All glucocorticoids	3 days
	Except: triamcinolone acetonide	30 days
Intramuscular	Betamethasone, dexamethasone, Methylprednisolone	5 days
	Prednisolone, prednisone	10 days
	Triamcinolone acetonide	60 days
Local injections (including periarticular, intra-articular, peritendinous and intratendinous)	All glucocorticoids	3 days
	Except: triamcinolone acetonide, Prednisolone, prednisone	10 days

When to apply for a TUE involving GCs

The chart below describes the three scenarios which may arise depending on whether the GC was administered in-competition or out-of-competition (in or prior to the washout period). Each pathway provides guidance on when players should apply for a TUE and when AFC would process such applications.



6. Mutual recognition of TUE approvals

- The AFC TUE Advisory Group recognises TUE approvals granted by FIFA and other confederations for players within AFC's registered testing pool, players participating in AFC competitions and players who are part of a major event organisation.
- NADOs do not have the authority to grant TUEs for players in an AFC registered testing pool or players participating in AFC competitions, provided that such players are international-level players according to the AFC ADRs. A TUE granted by a NADO is not automatically valid at international level and a request for recognition must be made.
- However, in the case of player joining an AFC registered testing pool or participating in an AFC competition at short notice, the AFC TUE Advisory Group recognises TUEs granted by NADOs in accordance with Article 4.4.3 of

the WADC. When considering such applications, the AFC TUE Advisory Group shall ensure, that:

- i. the respective NADO has followed the AFC's criteria (in accordance with Annex B of the AFC ADR and the International Standard for Therapeutic Use Exemptions) for granting a TUE;
- ii. the original application form, including all medical information submitted to the granting body, is provided to the AFC TUE Advisory Group (if the original application is not in English, it must be translated into English); and
- iii. the AFC TUE Advisory Group establishes the conformity of the application with the AFC TUE Policy.

7. TUE Approvals

The AFC is required to provide WADA with all TUEs approved for players who form part of an AFC registered testing pool or who participate in AFC competitions, as well as all supporting documentation.

Important note:

For more detailed information on the TUE application and granting process, please refer to the WADA International Standard TUEs at:

<http://www.wada-ama.org/en/what-we-do/Science-Medical/therapeutic-use-exemptions>

For more detailed information on the requirements for TUE applications in relation to particular diseases, please refer to the WADA Medical Information to Support the Decisions of TUECs at:

<http://www.wada-ama.org/en/what-we-do/Science-Medical/therapeutic-use-exemptions>

8. Data protection

The collection, storage, processing, disclosure and retention of personal information by the AFC in the TUE process shall comply with WADA's International Standard for the Protection of Privacy and Personal Information. It shall also be in compliance with Malaysia's Personal Data Protection Act 2010 ("PDPA") and applicable laws.

Player's acknowledgement

A player filing a TUE application acknowledges that:

- Player's TUE-related data as further specified in this Policy will be used in the

context of anti-doping programmes as indicated in the AFC ADR and the WADC. AFC may also use the player's TUE-related data for research purposes, in which case any personal information that could identify the player will be removed or changed before data is shared with other researchers or results are made public;

- AFC shall be principally responsible for ensuring the protection of the player's TUE- related data and is committed to complying with the International Standard for the Protection of Privacy and Personal Information issued by WADA and the PDPA.
- A player has certain rights in relation to TUE-related data, including rights to access and/or correct any inaccurate data and remedies with respect to any unlawful processing of data as further specified below;
- AFC will use, process and store the player's TUE-related data using the WADA Anti- Doping Administration and Management System ("ADAMS") and/or the AFC's administrative system(s) (the "AFC System"). AFC will disclose and transfer TUE- related data solely via ADAMS to recipients authorised to receive the information in accordance with the AFC ADR and the WADC, such as to designated anti-doping organisations ("ADOs") and WADA;
- Subject to local mandatory data protection laws, any dispute arising from this Policy or a decision made pursuant to the AFC ADR may be appealed exclusively before the bodies stipulated in the AFC ADR, including the Court of Arbitration for Sport (CAS).

The player further acknowledges the following:

Purpose of ADAMS

ADAMS enables ADOs, such as AFC and WADA, to conduct harmonised, coordinated and effective anti-doping programmes and to fulfil their respective responsibilities arising under the WADC. WADA and AFC rely upon ADAMS to fulfil their responsibilities under the WADC and in particular for the review of TUEs and its implications for anti-doping rule violation procedures.

Lawfulness of Processing

The fight against doping in sport is supported by the international community, and more than 180 countries have ratified the 2005 UNESCO International Convention against Doping in Sport ("the Convention"), which endorses the work of WADA and aims at ensuring the effectiveness of the implementation of the WADC. The worldwide anti-doping system pursuant to the WADC, as further reflected in the AFC ADR, is necessary for the protection of health, for moral, cultural and physical education and for the

principle of fair play, as well as to eliminate cheating in sport and to protect its future. The anti-doping measures undertaken by AFC and the processing of the players' data form part of the worldwide fight against doping in sport in furtherance of the aforementioned goals and are justified not only to guarantee the principle of fairness, but also to carry out important tasks in the public interest and to pursue legitimate interests as set out in the Convention, the WADC, national laws combating doping and the AFC ADR.

Categories of data concerned

In respect of TUEs, ADAMS and the AFC System contain data as specified in this Policy and in the TUE application form. This data may constitute sensitive personal data under national data protection or privacy laws in the country where the applying player resides and under WADA's international standards.

Disclosures

A player applying for a TUE acknowledges that all information pertaining to the application will be transmitted for review to all Therapeutic Use Exemption Committees (TUECs) or TUE Advisory Groups with authority under the WADC and WADA's international standards and, as required, other independent medical or scientific experts, and to all necessary staff involved in the management, review or appeal of TUEs and WADA. The player also acknowledges that the decision of the AFC TUE Advisory Group will be distributed to other relevant anti-doping organisations with testing and/or results management authority over the player and AFC Member Associations under the provisions of the WADC.

Should the assistance of external, independent experts be required, all details of the application shall be circulated without identifying the player concerned.

In addition, AFC and WADA, where appropriate, may enable other ADOs and service providers to access players' TUE-related data appearing in ADAMS to enable them to administer anti-doping programmes. Furthermore, WADA will access and process TUE-related data to fulfil its responsibilities under the WADC. The AFC and WADA and the other persons listed above will not disclose any of the TUE-related data other than to authorised persons within their organisations on a "need-to-know" basis.

TUE-related data may be made available through ADAMS to persons or parties located outside the country where a player resides. For example, players' information is shared with WADA, established in Switzerland and Canada, and may be shared with the ADOs in the country where a player's national association is registered and with the relevant confederation in order to allow them to perform their anti-doping programmes and comply with their obligations under WADC. The data protection and privacy laws of these countries may not always be equivalent to those in the player's own country. In any case, ADOs must comply with WADA's International Standards for the Protection of Privacy and Personal Information.

The AFC Advisory Group

The members of the AFC TUE Advisory Group, all independent experts and the staff of the AFC Anti- Doping Unit shall conduct all of their activities in strict confidence and shall sign appropriate confidentiality agreements. In particular, they shall keep the following information confidential:

- I. All medical information and data provided by the player and doctor(s) involved in the player's care.
- II. All details of the application including the name of the doctor(s) involved in the process.

If the player does not wish the AFC TUE Advisory Group or any TUEC to obtain any health information on his or her behalf, the player must notify his or her doctor in writing of the fact. As a consequence of such a decision, the player will not receive approval for a TUE or renewal of an existing TUE.

The Players' Rights

The player has certain rights under the applicable laws and under WADA's International Standard for the Protection of Privacy and Personal Information. Subject to the relevant legal conditions being fulfilled, these rights include:

- a) the right to be informed about the processing of his or her personal data;
- b) the right of access to and receipt of a copy of his or her personal data processed in ADAMS;
- c) the right to rectification if any personal data that is processed in ADAMS is inaccurate or incomplete;
- d) the right to erasure- i.e. the right to request deletion of any of his or her personal data that is processed in ADAMS and is no longer required for the relevant purposes;
- e) the right to restrict or prevent the processing of his or her personal data if, for example, he or she wants to contest the accuracy of the personal data or the personal data is no longer needed;
- f) the right to obtain a copy of the personal data processed in ADAMS;
- g) the right to object to AFC processing the personal data for particular purposes if AFC cannot provide compelling legitimate grounds for its processing. Players further acknowledge that the personal data processed by AFC is not subject to automated decision making, including profiling.

A player filing a TUE application acknowledges that according to the WADC, AFC has limited competence to erase or amend players' personal data. Should AFC, despite using its reasonable efforts, fail to comply with a players' request to erase or amend his or her data, the player will have to exercise his or her rights before WADA and/or the ADO of the country where his or her national association is domiciled.

Contact

In the event of any cause for complaint about the use of the player's TUE-related data or if the player has any questions relating to the processing of such data, the player may contact AFC (s.medicine@the-afc.com). In the event of any such complaint or question, the AFC shall use its reasonable efforts best to resolve the matter. If the player is not satisfied with AFC's response, the player may contact WADA and/or the ADO of the country of his or her national association. For further details, the player may also consult the athlete information notice, which is subject to change without notice, as found on the WADA website.

Complaint to data protection supervisory authority

If the inquiry cannot be resolved, the player has the right to lodge a complaint with the competent data protection supervisory authority in accordance with the data protection laws applicable to the player.

Security

The player notes that ADAMS is securely maintained in Switzerland and Canada. Stringent technological, organisational and other security measures have been applied to ADAMS to maintain the security of the data entered in it. In addition, AFC, WADA and ADOs have put in place internal and contractual guarantees to ensure that the player's data remains confidential and secure.

Data Retention

The player understands that it may be necessary to retain his or her TUE-related data in ADAMS for a minimum period of ten (10) years. The period of ten (10) years represents the period during which action may be commenced for an anti-doping violation under the WADC. Where the relevant anti-doping rules do not require the player's data to be retained for ten (10) years, the data will be deleted after an appropriately shorter period. For more information on data retention, the player may consult the Annex to WADA's International Standard for the Protection of Privacy and Personal Information.

Release

The player hereby releases AFC from all claims, demands, liabilities, damages, costs and expenses that may arise in connection with the processing of his or her TUE-related data through ADAMS, AFC System and other related data processing platforms.

ANNEX 1

The following AFC competitions require a TUE granted by the AFC or a TUE issued by another anti- doping organisation that is recognised by the AFC:

National Team Competitions

- 1.1. AFC Asian Cup;
- 1.2. AFC Asian Qualifiers;
- 1.3. AFC U23 Asian Cup;
- 1.4. AFC U20 Asian Cup;
- 1.5. AFC U17 Asian Cup;
- 1.6. AFC Women's Asian Cup;
- 1.7. Women's Olympic Football Tournament Asian Qualifier
- 1.8. AFC U20 Women's Asian Cup;
- 1.9. AFC U17 Women's Asian Cup;

Club Team Competitions

- 1.10. AFC Champions League Elite;
- 1.11. AFC Champions League Two;
- 1.12. AFC Challenge League;
- 1.13. AFC Women's Champions League;

Futsal & Beach Soccer Competitions

- 1.14. AFC Futsal Asian Cup;
- 1.15. AFC Futsal Club Championship;
- 1.16. AFC U-20 Futsal Asian Cup;
- 1.17. AFC Women's Futsal Asian Cup;
- 1.18. AFC Beach Soccer Asian Cup.

The above list of Competitions for which it is required to request an AFC TUE is not exhaustive and is subject to change. AFC may amend this list from time to time. The prevailing competitions are those listed on AFC.com. As a result, it is recommended to always verify the latest information available on the AFC.com

ANNEX 2

THERAPEUTIC USE EXEMPTION (TUE) APPLICATION FORM

PLEASE COMPLETE ALL SECTIONS (IN BLOCK CAPITALS). PLAYERS TO COMPLETE SECTIONS 1, 2, 3 AND 7; PHYSICIANS TO COMPLETE SECTIONS 4, 5 AND 6. ILLEGIBLE OR INCOMPLETE APPLICATIONS WILL BE RETURNED AND WILL NEED TO BE RE-SUBMITTED IN LEGIBLE AND COMPLETE FORM.
NOTE THAT THIS TUE APPLICATION FORM AS WELL AS THE ENTIRE MEDICAL FILE (INCL. ALL REPORTS AND DOCUMENTS) MUST BE IN ENGLISH.

1. PLAYER INFORMATION

SURNAME: _____ FIRST NAME(S): _____

FEMALE ☐ MALE ☐ DATE OF BIRTH: _____
(DAY/MONTH/YEAR)

ADDRESS: _____

CITY: _____ COUNTRY: _____

TEL.: _____ E-MAIL: _____
(WITH INTERNATIONAL CODE)

NATIONALITY: _____

NAME OF CLUB OR NATIONAL FOOTBALL ASSOCIATION: _____

IF YOU ARE AN ATHLETE WITH AN IMPAIRMENT, PLEASE INDICATE THE IMPAIRMENT:

Please mark the appropriate box:

- ☐ I AM PART OF THE FIFA INTERNATIONAL REGISTERED TESTING POOL (IRTP)
- ☐ I AM PART OF THE AFC INDIVIDUAL ATHLETE REGISTERED TESTING POOL (AITP)
- ☐ I AM PART OF THE AFC ELITE TESTING POOL (ETP)
- ☐ I AM PART OF THE AFC PRE-COMPETITION TESTING POOL (PCTP)
- ☐ I AM PARTICIPATING IN AN AFC COMPETITION: _____
(NAME OF AFCCOMPETITION)
- ☐ I AM PART OF A NATIONAL ANTI-DOPING ORGANISATION (NADO) TESTING POOL: _____
(NAME OF NADO)
- ☐ REQUEST FOR RECOGNITION OF TUE ISSUED BY NADO
- ☐ NONE OF THE ABOVE
- ☐ THIS TUE APPLICATION MADE FOR USE DURING:
- ☐ IN-COMPETITION ☐ OUT-OF-COMPETITION

Reply to be sent:

- ☐ by fax number: _____
(Please include country and area code)
- ☐ by e-mail address: _____
- ☐ by postal address: _____

3. RETROACTIVE APPLICATIONS

IS THIS A RETROACTIVE APPLICATION? Yes ☐ No ☐

If yes, on what date was treatment started?

DO ANY OF THE FOLLOWING EXCEPTIONS APPLY? (ARTICLE 4.1 OF THE ISTUE)

- ☐ You required emergency or urgent treatment of medical condition.
- ☐ There was insufficient time, opportunity or other exceptional circumstances that prevented you from submitting the TUE application, or from having it evaluated, before getting tested.
- ☐ You were not permitted or required to apply in advance for a TUE as _____ per anti-doping rules.
- ☐ You tested positive after using a substance out-of-competition that was only prohibited in-competition e.g. S9 glucocorticoids

Please explain (if necessary, attach further documents):

- ☐ Other retroactive applications (ISTUE, article 4.3)

In rare and exceptional circumstances notwithstanding any other provision in the ISTUE, a player may apply for and be granted retroactive approval for their TUE if, considering the purpose of the Code, it would be manifestly unfair not to grant a retroactive TUE.

In order to apply under article 4.3, please include a full reasoning and attach all necessary supporting documentation.

Please explain (if necessary, attach further documents):

PHYSICIAN TO COMPLETE SECTIONS 4, 5 AND 6

4. MEDICAL INFORMATION (PLEASE ATTACH RELEVANT MEDICAL DOCUMENTATION)

DIAGNOSIS WITH DETAILED MEDICAL INFORMATION (SEE NOTE 1 BELOW):

NOTE 1 – DIAGNOSIS

Evidence confirming the diagnosis must be attached to and forwarded with this application. The medical information must include a comprehensive medical history and the results of all relevant examinations, laboratory investigations and imaging studies.

Copies of the original reports or letters should be included whenever possible. Evidence should be as objective as possible in the clinical circumstances. In the case of non-demonstrable conditions, independent supporting medical opinion will assist this application.

If a permitted medication can be used to treat the medical condition, please provide justification for the therapeutic use exemption for the prohibited medication.

WADA maintains a series of guidelines to assist players and physicians in the preparation of complete and thorough TUE applications. These TUE Guidelines can be accessed by entering the search term “Checklist” on the WADA website: <https://www.wada-ama.org>.

5. MEDICATION DETAILS (CONTINUE ON SEPARATE SHEET IF NECESSARY)

PROHIBITED SUBSTANCE(S) – GENERIC NAME	DOSE	ROUTE OF ADMINISTRATION	FREQUENCY OF ADMINISTRATION	DURATION OF TREATMENT
1.				
2.				
3.				
4.				

6. MEDICAL PRACTITIONERS'S DECLARATION

I certify that the information in sections 4 and 5 above is accurate. I acknowledge and agree that my personal information may be used by AFC to contact me regarding this TUE application, to verify the professional assessment in connection with the TUE process, or in connection with anti-doping rule violation investigations or proceedings. I further acknowledge and agree that my personal information will be uploaded to the Anti-Doping Administration and Management System (ADAMS) for these purposes (see FIFA's Data Protection Portal and the ADAMS Privacy Policy for more details).

I certify that the information in sections 2 and 3 above is accurate, and that the above-mentioned treatment is medically appropriate.

NAME: _____

MEDICAL SPECIALITY: _____

LICENCE NUMBER: _____ LICENCE BODY: _____

ADDRESS: _____

TEL.: _____ EMAIL: _____

MOBILE: _____ FAX: _____

SIGNATURE OF MEDICAL PRACTITIONER

DATE

7. TUE PRIVACY AND PERSONAL DATA PROTECTION NOTICE (“NOTICE”)

In compliance with Malaysia’s *Personal Data Protection Act 2010* (“Act”) and its regulations, this document is issued to all applicable persons whose personal data are used and processed by the Asian Football Confederation (AFC) in connection with your submission of a TUE application.

In order to process and perform all required obligations under the AFC Therapeutic Use Exemption (TUE) Policy (“Policy”), the AFC may be required to collect, hold, use, delete, disclose, transfer, administer and process your personal data. The use of your personal data by the AFC shall be for the purposes as indicated below:

SOURCE AND TYPES OF PERSONAL DATA

Such personal data/information shall include without limitation:

- The information provided by you or your physician(s) on the TUE Application Form (including your name, date of birth, address, email address, telephone number, any contact details, sport and discipline, the diagnosis, medication, and treatment relevant to your application);
- Supporting medical information and records provided by you or your physician(s); and
- Assessments and decisions on your TUE application by ADOs (including WADA) and their TUE Committees and other TUE experts, including communications with you and your physician(s), relevant ADOs or support personnel regarding your application.

PURPOSES AND USE

The AFC will use or grant others (as defined below) the rights to use your personal data for the following purposes including without limitation:

- Your personal data will be used in order to process and evaluate the merits of your TUE application in accordance with the International Standard for Therapeutic Use Exemptions. In some instances, it could be used for other purposes in accordance with the World Anti-Doping Code (“Code”), the International Standards, and the anti-doping rules of ADOs with authority to test you. This includes:
 - Results management, in the event of an adverse or atypical finding based on your sample(s) or the Athlete Biological Passport; and
 - In rare cases, investigations or related procedures in the context of a suspected Anti-Doping Rule Violation (ADRV).
- Communication with you and delivery of information relating to the Policy (including the delivery of any form, notice or other documents to you);
- Processing of any travel, lodging or transportation arrangements;
- Necessary performance of obligations which are incidental, ancillary or in furtherance to;
- Internal record keeping (including for the purposes of administration, auditing, data analysis, research, benchmarking and/or statistical analysis);
- Verification of identity for purposes of accreditation;
- Compliance with any legal and/or regulatory requirements

TYPES OF RECIPIENTS AND THIRD-PARTY DISCLOSURE

The AFC may disclose your personal data to the following category of third parties for the purposes as indicated above and may collect, process and store your personal data in connection with the purpose within or outside Malaysia as follows:

- AFC employees;
- FIFA, confederations and/or AFC Member Associations;
- Agents, partners, representatives and/or service providers;
- Auditors, business consultants, accountants, lawyers or other professional advisors and/or consultants as the AFC may deem necessary and appropriate;
- Any person to whom the AFC is compelled to or required under law or in response to a local, state or federal authority, industry regulator, enforcement agency, statutory authority, courts of law,

tribunals, arbitration centres, commissions, councils or associations legally authorised by law.

Your personal data, including your medical or health information and records, may also be shared with the following:

- ADO(s) responsible for making a decision to grant, reject or recognise your TUE, as well as their delegated third parties (if any). The decision to grant or deny your TUE application will also be made available to ADOs with testing authority and/or results management authority over you;
- WADA authorised staff;
- Members of the TUE Committees (TUECs) of each relevant ADO and WADA; and
- Other independent medical, scientific or legal experts, if needed.

Note that due to the sensitivity of TUE information, only a limited number of ADO and WADA staff will receive access to your application. ADOs (including WADA) must handle your personal data in accordance with the International Standard for the Protection of Privacy and Personal Information (ISPPPI). You may also consult the ADO to which you submit your TUE application to obtain more details about the processing of your personal data.

Your personal data will also be uploaded to ADAMS by the ADO that receives your application so that it may be accessed by other ADOs and WADA as necessary for the purposes described above. ADAMS is hosted in Canada and is operated and managed by WADA. For details about ADAMS, and how WADA will process your personal data, consult the ADAMS Privacy Policy ([ADAMS Privacy Policy](#)).

FAIR AND LAWFUL PROCESSING

When you sign the Player Declaration, you are confirming that you have read and understood this TUE Privacy and Personal Data Protection Notice. Where appropriate and permitted by applicable law, ADOs and other parties mentioned above may also consider that this signature confirms your express consent to the personal data processing described in this notice. Alternatively, ADOs and these other parties may rely upon other grounds recognised in law to process your personal data for the purposes described in this notice, such as the important public interests served by anti-doping, the need to fulfil contractual obligations owed to you, the need to ensure compliance with a legal obligation or a compulsory legal process, or the need to fulfil legitimate interests associated with their activities.

YOUR RIGHTS AND OBLIGATIONS

It is necessary for you to provide accurate and up to date personal data to the AFC to enable the AFC to process your data in connection with the above said purposes.

Subject to the AFC's rights of refusal under the Act and reasonable notice, you are entitled to:

- Request access to your personal data that is processed by the AFC;
- Request the revision of any personal data held by us which may be inaccurate, incomplete or out of date;
- Limit the AFC's processing of your personal data by expressly withdrawing your consent previously granted in respect to marketing and promotional purposes.

You have rights with respect to your personal data under the ISPPPI, including the right to a copy of your personal data and to have your personal data corrected, blocked or deleted in certain circumstances. You may have additional rights under applicable laws, such as the right to lodge a complaint with a data privacy regulator in your country.

Where the processing of your personal data is based on your consent, you can revoke your consent at any time, including the authorisation to your physician to release medical information as described in the Player Declaration. To do so, you must notify your ADO and your physician(s) of your decision. If you withdraw your consent or object to the personal data processing described in this notice, your TUE will likely be rejected as ADOs will be unable to properly assess it in accordance with the Code and International Standards.

In rare cases, it may also be necessary for ADOs to continue to process your personal data to fulfil obligations under the Code and the International Standards, despite your objection to such processing or withdrawal of consent (where applicable). This includes processing for investigations or proceedings related to ADRV, as well as processing to establish, exercise or defend against legal claims involving you, WADA and/or an ADO.

SAFEGUARDS

All information contained in a TUE application, including the supporting medical information and records, and any other information related to the evaluation of a TUE request, must be handled in accordance with the principles of strict medical confidentiality. Physicians who are members of a TUE Committee and any other experts consulted must be subject to confidentiality agreements.

Under the ISPPPI, ADO staff must also sign confidentiality agreements, and ADOs must implement strong privacy and security measures to protect your personal data. The ISPPPI requires ADOs to apply higher levels of security to TUE information because of the sensitivity of this information. You can find information about security in ADAMS by consulting the response to “[How is your information protected in ADAMS?](#)” in the [ADAMS Privacy and Security FAQs](#).

RETENTION

Your personal data will be retained by ADOs (including WADA) for the retention periods described in Annex A of the ISPPPI. TUE certificates or rejection decisions will be retained for ten (10) years. TUE application forms and supplementary medical information will be retained for twelve (12) months from the expiry of the TUE. Incomplete TUE applications will be retained for twelve (12) months.

CONTACT

Consult AFC at s.medicine@the-afc.com for questions or concerns about the processing of your personal data. To contact WADA, use privacy@wada-ama.org

8. PLAYER'S DECLARATION

I, _____, certify that the information set out at sections 1, 2 and 3 are accurate. I authorise my physician(s) to release the medical information and records that they deem necessary to evaluate the merits of my TUE application to the following recipients: the Anti-Doping Organization(s) (ADO) responsible for making a decision to grant, reject or recognise my TUE; the World Anti-Doping Agency (WADA), who is responsible for ensuring that determinations made by ADOs respect the ISTUE; the physicians who are members of relevant ADO(s) and WADA TUE Committees (TUECs) who may need to review my application in accordance with the World Anti-Doping Code and International Standards; and, if needed to assess my application, other independent medical, scientific or legal experts.

I further authorise AFC to release my complete TUE application, including supporting medical information and records, to other ADO(s) and WADA for the reasons described above, and I understand that these recipients may also need to provide my complete application to their TUEC members and relevant experts to assess my application.

By signing this declaration, I am also declaring that I have read, understood and agreed to the terms of the TUE Privacy and Personal Data Protection Notice ("Notice") under section 7 and I am expressly consenting to and authorising the AFC and third parties as listed in the Notice to collect, hold, use, delete, disclose, transfer, administer and process in any other way, all my personal data (including sensitive personal data and personal data of other parties provided by me) (hereinafter referred to as "Personal Data") given now or that is subsequently obtained from time to time for purposes as provided in the Notice.

By signing this declaration, I further confirm that all Personal Data that I have provided is true, up to date and accurate. Should there be any changes to any of my Personal Data, I shall notify the AFC immediately. I understand that I have the rights to access and correct my Personal Data by contacting the AFC at dataprotection@the-afc.com, I understand that the AFC may take steps to verify my identity before fulfilling my request for access to my Personal Data.

Unless it prevents the AFC from performing its obligations to me or goes against the purposes as listed in the Notice. I can withdraw any part of this consent by letting the AFC know in writing.

PLAYER'S SIGNATURE: _____ DATE: _____

PARENT/GUARDIAN'S SIGNATURE: _____ DATE: _____

(If the player is a minor or has an impairment preventing him/her from signing this form, a parent or guardian shall sign with or on behalf of the player.)

**INCOMPLETE OR ILLEGIBLE APPLICATIONS WILL BE RETURNED AND WILL NEED TO BE
RESUBMITTED**

PLEASE SUBMIT THE COMPLETED FORM TO THE CONFIDENTIAL EMAIL ADDRESS OF THE AFC ANTI-DOPING UNIT. AS A FIRST STEP, PLEASE SEND A FORMAL EMAIL ONLY TO s.medicine@the-afc.com, WITHOUT ATTACHING THE TUE APPLICATION FORM OR RELEVANT MEDICAL DOCUMENTS. **AFC WILL SEND YOU A PERSONALISED LINK TO AN ENCRYPTED FOLDER. YOU WILL THEN BE ASKED TO UPLOAD THE TUE APPLICATION FORM AND THE RELEVANT MEDICAL DOCUMENTS INTO THAT ENCRYPTED FOLDER. PLEASE NEVER SEND PERSONAL INFORMATION OVER EMAIL**

TREATMENT MAY BE ADMINISTERED ONLY ONCE AFC HAS APPROVED THE TUE REQUEST!